Harrow Health, Inc.

NASDAQ:HROW

Drug Manufacturers - Specialty & Generic

Healthcare
$32.16 +0.29%

+$0.12 today

Market cap
$1.21B
Beta
0.28
P/E (TTM)
-104.7
EPS (TTM)
-$0.40
52W Low $28.54High $54.85

Volume 0.87M

Average 0.75M

HROW Other Financing Activities

Financing cash flows not reported separately.

Harrow Health, Inc.NASDAQ: HROW

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities outflow grows to $0

Q1 FY2026 other financing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other financing activities was -$12.17M. Over 3 fiscal years it compounded at +374.7% a year.

Context

  • Other financing activities amounted to 9.2% of revenue in FY2025, up 8.6 pp from a year earlier.
  • Other financing activities grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$3.04M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$25.04M+1899.7% YoY
LTMMar 2026
-$12.17M-2165.4% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+1899.7%——
3-year CAGR+374.7%——
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
(25.04M) USD
Year-over-year change
-1899.7%

Other Financing Activities vs competitors

How HROW compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2165.4% is the lowest of 7, against a peer median of -99.4%.
  • Other financing activities amounts to 4.5% of revenue for HROW, versus a peer median of 33.2%.
HROW Competitors
Other Financing Activities for HROW and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$15.53T USD+92313235.1%—4662722470.8%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$130.88M USD+310.6%—19.2%
HROWHarrow Health, Inc.LTM Mar 2026$12.17M USD-2165.4%+374.7%4.5%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$3.59M USD-136.4%-24.2%47.2%
TTRXTurn Therapeutics Inc.LTM Mar 2026$1.07M USD———
OCSOculis Holding AGLTM Mar 2026CHF 1.02M CHF-107.2%—202.6%
BLCOBausch + Lomb CorporationLTM Jun 2026$499.55K USD-98.7%-78.4%0.0%
KODKodiak Sciences Inc.LTM Sep 2026$0 USD———
OCULOcular Therapeutix, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding HROW) —-99.4%-51.3%33.2%

Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(18.01M)(14.09M)(24.41M)(17.48M)(5.14M)
Depreciation & Amortization2.4M3.67M12.34M14.54M19.68M
Deferred Income Tax00000
Stock-Based Compensation5.75M7.97M15.7M17.62M12.5M
Change in Working Capital(253K)(5.57M)(7.14M)(44.63M)185K
Accounts Receivables(1.83M)(1.86M)(30.34M)(80.23M)5.01M
Inventory(255K)(2.32M)(4.33M)165K(2.82M)
Accounts Payables1.73M933K31.8M37.5M(4.61M)
Other Working Capital103K(2.32M)(4.26M)(2.06M)2.6M
Other Non-Cash Items15.2M9.72M7.35M7.75M16.64M
Operating Cash Flow5.08M1.71M3.84M(22.2M)43.86M
Capital Expenditures(28.51M)(7.77M)(152.55M)(38.67M)(1.1M)
Acquisitions (Net)9.83M000(4.36M)
Purchases of Investments00000
Sales of Investments9.83M005.51M0
Other Investing Activities(36.55M)854K(151.09M)(37.08M)(215K)
Investing Cash Flow(18.69M)(1.74M)(152.55M)(33.16M)(5.46M)
Debt Repayment71.07M31.72M74.64M29.78M11.84M
Common Stock Issued022.66M64.52M0467K
Common Stock Repurchased00000
Dividends Paid(127K)0000
Other Financing Activities(19.12M)(234K)(12.63M)(1.25M)(25.04M)
Financing Cash Flow51.47M54.14M126.53M28.53M(12.72M)
Effect of Forex Changes00000
Net Change in Cash37.87M54.1M(22.19M)(26.84M)25.68M
Free Cash Flow(23.43M)(6.07M)(148.71M)(60.88M)42.76M

Harrow Health, Inc.

NASDAQ:HROW

Intrinsic Alpha fair value

Locked

Current Price

$32.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.